Nuvig Therapeutics

Nuvig Therapeutics, Inc. is a privately held, clinical-stage biotechnology company headquartered at 3450 Hillview Avenue, Palo Alto, California, developing next-generation immunomodulators for chronic autoimmune and inflammatory disease. Its lead investigational candidate, NVG-2089, is an engineered Fc fragment designed to selectively engage type II Fc receptors and harness an endogenous regulatory mechanism that resolves autoimmune dysregulation while preserving normal immune function; the first patient was dosed in a Phase 2 trial in chronic inflammatory demyelinating polyneuropathy (CIDP) in May 2025. The company announced a $161 million Series B financing in December 2024. Nuvig is a therapeutics developer, not a software vendor: as of August 2026 it publishes no developer portal, API reference, SDK, GitHub organization, or machine-readable API contract of any kind. Its public web surface is a corporate WordPress site covering science, pipeline, team, news and careers, from which the only machine-readable artifact published is a Yoast-generated llms.txt.

Nuvig Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Immunology, and Autoimmune Disease.

Nuvig Therapeutics’ developer surface includes product news, engineering blog, and 16 more developer resources.

🌐 Visit website 📡 Source on GitHub

11.5/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0

0 APIs

CompanyBiotechnologyPharmaceuticalsImmunologyAutoimmune DiseaseTherapeuticsClinical TrialsLife SciencesUnited States

Kin Score

Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0

Composite quality — 11.5/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.4 / 17

Commercial Clarity 3.6 / 17

Operational Transparency 0.0 / 11

Governance 0.0 / 10

Discoverability 4.9 / 9

Regulatory Posture 2.6 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/nuvig-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt

LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Contact

Contact

Commercial 2

Pricing, plans, and the legal terms of use

TermsOfService

TermsOfService

PrivacyPolicy

PrivacyPolicy

Company 9

The organization behind the API

Website

About

News

Blog

BlogFeeds

Careers

LinkedIn

Twitter

Twitter

Investors

Investors

Scroll for all 9

Other 4

Properties that don't map to a standard resource type

Science

Pipeline

Team

CookiePolicy

Source (apis.yml)

aid: nuvig-therapeutics
name: Nuvig Therapeutics
description: 'Nuvig Therapeutics, Inc. is a privately held, clinical-stage biotechnology company headquartered at 3450 Hillview
  Avenue, Palo Alto, California, developing next-generation immunomodulators for chronic autoimmune and inflammatory disease.
  Its lead investigational candidate, NVG-2089, is an engineered Fc fragment designed to selectively engage type II Fc receptors
  and harness an endogenous regulatory mechanism that resolves autoimmune dysregulation while preserving normal immune function;
  the first patient was dosed in a Phase 2 trial in chronic inflammatory demyelinating polyneuropathy (CIDP) in May 2025.
  The company announced a $161 million Series B financing in December 2024. Nuvig is a therapeutics developer, not a software
  vendor: as of August 2026 it publishes no developer portal, API reference, SDK, GitHub organization, or machine-readable
  API contract of any kind. Its public web surface is a corporate WordPress site covering science, pipeline, team, news and
  careers, from which the only machine-readable artifact published is a Yoast-generated llms.txt.'
image: https://nuvigtx.com/wp-content/uploads/2022/04/bg-logo-nuvig.svg
url: https://raw.githubusercontent.com/api-evangelist/nuvig-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profile
x-tier-reason: enrichment-pass
specificationVersion: '0.20'
x-enrichment:
  date: '2026-08-04'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Nuvig is a clinical-stage biotech whose product is a drug candidate (NVG-2089), not software — nuvigtx.com is a
    five-page corporate WordPress site with no /developers, /api or /docs path, no GitHub organization, and no package on
    any registry.
  evidence:
  - url: https://nuvigtx.com/developers
    status: 404
  - url: https://nuvigtx.com/openapi.json
    status: 404
  - url: https://nuvigtx.com/.well-known/agent-card.json
    status: 404
  - url: https://nuvigtx.com/llms.txt
    status: 200
  checked: '2026-08-04'
created: '2026-08-04'
modified: '2026-08-04'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Immunology
- Autoimmune Disease
- Therapeutics
- Clinical Trials
- Life Sciences
- United States
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/nuvig-therapeutics-domain-security.yml
- type: Website
  url: https://nuvigtx.com/
- type: About
  url: https://nuvigtx.com/science/
- type: Science
  url: https://nuvigtx.com/science/
- type: Pipeline
  url: https://nuvigtx.com/pipeline/
- type: Team
  url: https://nuvigtx.com/team/
- type: News
  url: https://nuvigtx.com/news/
- type: Blog
  url: https://nuvigtx.com/news/
- type: BlogFeeds
  url: https://nuvigtx.com/feed/
- type: Careers
  url: https://nuvigtx.com/careers/
- type: Contact
  url: https://nuvigtx.com/contact/
- type: TermsOfService
  url: https://nuvigtx.com/terms-of-use/
- type: PrivacyPolicy
  url: https://nuvigtx.com/privacy-policy/
- type: CookiePolicy
  url: https://nuvigtx.com/cookie-policy/
- type: LinkedIn
  url: https://www.linkedin.com/company/nuvig-therapeutics-inc
- type: Twitter
  url: https://x.com/nuvigtx
- type: Investors
  url: https://www.hiive.com/securities/nuvig-therapeutics-stock
- type: LLMsTxt
  url: llms/nuvig-therapeutics-llms.txt